Conduction System Pacing After TAVR Linked to Improved Outcomes in New Meta-Analysis

Why It Matters

CSP offers a more physiological pacing strategy that could improve cardiac function and reduce costly rehospitalizations for TAVR patients, reshaping post‑procedure care standards.

Key Takeaways

• Meta-analysis pooled 800 TAVR patients with post‑procedure pacemakers.
• CSP showed shorter paced QRS duration than traditional right ventricular pacing.
• Left ventricular ejection fraction improved after 15 months with CSP.
• Heart‑failure rehospitalization risk decreased in CSP group.

Pulse Analysis

Transcatheter aortic valve replacement has become the preferred treatment for severe aortic stenosis, yet up to 30% of patients develop conduction abnormalities that necessitate permanent pacing. Traditional right ventricular pacing, while effective for rhythm control, disrupts the heart’s natural electrical pathway, potentially leading to dyssynchronous contraction and long‑term ventricular dysfunction. Clinicians have therefore been exploring alternatives that preserve physiological activation, with conduction system pacing—either His‑bundle or left bundle branch pacing—emerging as a promising option.

The recent meta‑analysis, published in Heart Rhythm O2, aggregated data from eight clinical investigations, encompassing roughly 400 patients in each arm. Over a median 15‑month follow‑up, mortality outcomes were comparable, but CSP demonstrated clear electrophysiological advantages: paced QRS complexes were significantly narrower, indicating more synchronized ventricular depolarization. Moreover, patients receiving CSP exhibited higher left ventricular ejection fractions and experienced fewer heart‑failure readmissions, suggesting tangible functional benefits beyond mere rhythm correction.

If these findings hold in larger, randomized trials, CSP could shift the post‑TAVR pacing paradigm. Shorter QRS duration and preserved ejection fraction translate into better quality of life and potentially lower healthcare expenditures linked to rehospitalization. Hospitals and device manufacturers may accelerate adoption of dedicated CSP leads and training programs, while payers could reassess reimbursement models to favor strategies that demonstrate cost‑effective outcomes. Ultimately, embracing CSP could enhance long‑term survivorship and align TAVR care with the broader goal of physiologic cardiac therapy.